UNSPSC 51102860: Loteprednol/tobramycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102860 Loteprednol/tobramycin, a Commodity code, shows little relevant recent activity grounded in actual procurement under the code's scope. The two most recent state and local opportunities posted under this code diverge significantly from the pharmaceutical product named in the code itself. The Illinois Department of Public Health's August 2026 piggyback award through MMCAP Infuse to Chartwell Rx LLC supplied Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets—antibiotic products unrelated to the loteprednol/tobramycin combination specified by the code. Seminole County, Florida's June 2026 IFB for Naloxone and Safe Drug Deactivation Systems similarly falls outside the code's nominal scope, targeting emergency opioid-reversal agents and drug disposal equipment rather than the ophthalmic corticosteroid-antibiotic formulation the code denotes. Both opportunities represent pharmaceutical procurement by state and local health agencies, but neither targets the loteprednol/tobramycin product family.

The Illinois award, totaling $2,999,999.11 over 12 months with two renewal options, was issued as an Invitation for Bid with response due September 11, 2026, and was directed to Chartwell Rx LLC. Seminole County's Naloxone procurement required quarterly deliveries to the County Community Health Building in Sanford, with an IFB response deadline of July 26, 2023, and contract terms of two years plus one optional renewal. Neither the Illinois Department of Public Health nor Seminole County has posted a competitive open solicitation for loteprednol/tobramycin products in the recent opportunity window. State and local health agencies do source pharmaceutical products through piggyback and direct IFB vehicles, but the code's current signal reflects misclassification rather than active demand for this specific ophthalmic medication.